 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The new BTK inhibitor Zanubrutinib is used to treat relapsed/refractory marginal zone lymphoma

Clin Cancer Res: The new BTK inhibitor Zanubrutinib is used to treat relapsed/refractory marginal zone lymphoma

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

misoprostol side effects

parlodel side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Marginal zone lymphoma (MZL) is a rare type of non-Hodgkin's lymphoma, accounting for about 8-12% of non-Hodgkin's lymphoma, and its malignant cells show consistent dependence on B cell receptor signals

Lymphoma

Zanubrutinib is a potential, highly specific, irreversible, new-generation selective Bruton tyrosine kinase inhibitor

Zanubrutinib has shown good anti-tumor activity in Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia /small lymphocytic lymphoma and mantle cell lymphoma

This study is a phase II clinical trial (MAGNOLIA) to evaluate the efficacy and safety of Zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma

Patients with relapsed/refractory marginal zone lymphoma receive Zanubrutinib 160 mg twice a day until the disease progresses or intolerable toxicity occurs

DOR rate

A total of 68 patients were recruited

The ORR assessed by the independent review committee was 68.

PFS rate

Zanubrutinib treatment is well tolerated, and most of the side effects are grade 1-2

side effects

All in all, Zanubrutinib has shown a high objective remission rate and complete remission rate in patients with relapsed/refractory marginal zone lymphoma, and it has a long-lasting disease control effect and good safety

Zanubrutinib has shown a high objective remission rate and complete remission rate in patients with relapsed/refractory marginal zone lymphoma, and has a long-lasting disease control effect and good safety

Original source:

Stephen Opat, Alessandra Tedeschi, Kim Linton, et al.

The MAGNOLIA Trial: Zanubrutinib, a Next -Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed / Refractory Marginal Zone Lymphoma

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Erlotinib hydrochloride

CAS No.: 183319-69-9

Industrial Grade or Medical grade

$1/MT EXW

6-Thioguanine

CAS No.: 154-42-7

Industrial Grade or Medical grade

$1/MT EXW

Vinblastine sulfate

CAS No.: 143-67-9

Industrial Grade or Medical grade

$1/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.